Every material Form 8-K Apyx Medical Corp has filed with the SEC since August 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Apyx Medical reported third-quarter 2026 revenue of $14.0 million, up 9% from $12.9 million a year earlier, led by a 17% rise in Surgical Aesthetics sales. The net loss attributable to stockholders narrowed to $1.8 million, or $0.04 per share, from $2.0 million, or $0.05 per share. The company reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million and lowered its operating expense target to $41.0 million to $42.5 million.
Q3 2026 total revenue was $14.0 million versus $12.9 million in Q3 2025; OEM revenue fell 42% to about $1.1 million.
Net loss attributable to stockholders was $1.8 million ($0.04 per share), compared with $2.0 million ($0.05 per share) a year earlier.
Adjusted EBITDA was $0.4 million, compared with a loss of $0.1 million in Q3 2025.
FY2026 revenue guidance of $59.0 million to $60.0 million was reaffirmed; operating expense guidance was cut to $41.0 million to $42.5 million from less than $45.0 million.
Apyx Medical announced on September 29, 2026 that a prospective clinical study of its Renuvion technology was published in Plastic and Reconstructive Surgery — Global Open. The filing contains no financial results, guidance, or changes to the company's business, and the study covered seven patients, with six completing the Day 180 visit.
Day 180 results (n=6) showed a 30% increase in elastin fiber density and a 34% reduction in inflammation versus untreated control tissue.
Seven patients undergoing lower rhytidectomy (facelift) were enrolled at two U.S. investigational sites; six completed the Day 180 visit.
The study was published in Plastic and Reconstructive Surgery — Global Open, and the press release is filed as Exhibit 99.1.
At its August 6, 2026 annual meeting, Apyx Medical stockholders approved the company's 2026 Share Incentive Plan, elected all five director nominees, ratified RSM US LLP as auditor for 2026, and approved a non-binding advisory vote on executive compensation. The filing reports only vote outcomes and does not describe changes to the company's financial results.
2026 Share Incentive Plan approved with 16,186,776 votes for, 2,755,882 against and 3,276,000 abstaining
All five director nominees were elected to serve until the 2027 annual meeting
RSM US LLP ratified as independent registered public accounting firm for the year ending December 31, 2026, with 29,814,618 votes in favor
Non-binding say-on-pay resolution approved with 21,458,554 votes for and 669,298 against
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Apyx Medical Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →